SurgaColl™ Technologies Ltd JG07 Hamilton Building Dublin City University

Glasnevin, Dublin 9 Ireland

info@surgacoll.com www.surgacoll.com

SG

C-H

C-B

R-0

01-

00 Distributed by:

HydroxyCollTM

Bone Graft Substitute

SG

C-H

C-B

R-0

01-

00

SurgaColl™ Technologies Ltd JG07 Hamilton Building, Dublin City University, Glasnevin, Dublin 9, Ireland

Surgical Innovation Delivered Naturally

HydroxyColl

HydroxyColl is a 3rd generation bone graft substitute, based on a new understanding of bone healing & regeneration. The unique combination of naturally-derived materials, with the following features creates the optimum biomimetic microenvironment1,2,3,4,5,6, for biomaterial-driven inductive performance;

• Porosity (>90% interconnected collagen structure)7,8,9

• Stiffness (optimized for bone cell differentiation)10,11,12,13 • Biomaterial (resorbable crystalline Hydroxyapatite)14

Inductive Performance

HydroxyColl’s unique composition demonstrates a capacity for bone mineralization15,16. By using host cells with an optimized biomimetic microenvironment, HydroxyColl delivers potent inductive performance, without the addition of surgically-delivered osteogenic factors (superior to osteoconductive synthetic bone grafts).

HydroxyColl is capable of delivering healing performance equivalent to the host’s own bone i.e. Autograft.

Vascularisation

HydroxyColl is unique in its ability to actively drive early blood vessel formation within the newly-formed bone tissue. This potent vascularization property arises from the optimized structure of the scaffold17,18 (porosity, stiffness, & biomaterial surface area). HydroxyColl’s biomimetic collagen structure, together with increased vasculogenic potential leads to rapidly increased bone healing rates14 without compromising its superior quality of repair.

1. O’Brien FJ et al. Biomaterials. 2005; 26(4):433-412. Farrell E et al. Tissue Eng. 2006 Mar; 12(3):459-68 3. O’Brien FJ et al. Technol Health Care. 2007; 15(1):3-17. 4. Farrell E et al. Technol Health Care. 2007;15(1):19-31.5. Byrne EM et al. J Mater Sci Mater Med. 2008 Nov; 19(11):3455-63.6. Haugh MG et al. J Biomed Mater Res A. 2009 May; 89(2):363-9.7. Murphy CM et al. Cell Adh Migr. 2010 Jul 9; 4(3).

8. Murphy CM et al. Biomaterials. 2010 31: 461–466.9. Murphy CM et al. J Biomed Mater Res A. 2016 Jan; 104(1):291-304.10. Tierney CM et al. J Biomed Mater Res A. 2009 Sep 2 91A(1):92-10111. Keogh MB et al. Acta Biomater. 2010 6(11):4305-13. 12. Haugh MG et al. Tissue Eng Part A. 2011 May; 17(9-10):1201-8.13. Murphy CM et al. J Mech Behav Biomed Mater. 2012 Jul; 11:53-62.14. Lyons F et al. Clin Orthop Relat Res. 2014 Apr; 472(4):1318-28

HydroxyColl Bone Graft Substitute

www.surgacoll.com | info@surgacoll.com | twitter @surgacoll

Faster Bone Healing

HydroxyColl’s combination of optimized composition & structure accelerates replacement of the scaffold by the body’s own newly formed bone tissue14,19. Specifically, the naturally derived materials (actively drive blood vessel formation17,18 & bone mineralization19,22,23), coupled with an incredibly high porosity (99%) & pore interconnectivity (rapid resorption of the implant) results in faster remodeling compared to patient’s own bone.

Superior Bone Quality

HydroxyColl produces faster restoration of the natural physiology of healthy bone tissue14,19. The osteostimulative HydroxyColl promotes a faster return to anatomically normal bone microstructure. Earlier growth of new blood vessels, within the interconnected porous structure, drives faster recruitment of bone forming cells to the centre of the healing defect. This highly vascularized and developing bone extracellular matrix (ECM), formed within the remodeled HydroxyColl scaffold, produces superior mature bone formation24,25,26.

Natural Haemostat

HydroxyColl is CE mark approved & complies with the Essential Requirements of the Medical Device Directive, specifically that the safety & quality of HydroxyColl has been independently verified.

Collagen implants and dressings have been extensively used to facilitate the natural process of wound healing. HydroxyColl’s highly purified fibrillar Type 1 collagen offers intrinsic hemostatic properties, offering effective control of bleeding when applied to the wound site.

15. Gleeson JP et al. Eur Cell Mater 2010; 20: 218-230. 16. Murphy CM et al. Acta Biomater. 2014 May; 10(5):2250-8.17. Duffy GP et al. Eur Cell Mater. 2011; 21:15-30.18. McFadden TM et al. Acta Biomater. 2013 Dec; 9(12):9303-16.19. David F et al. J Tissue Eng Regen Med. 2015 Oct; 9(10):1193-9.20. Duffy GP et al. Eur Cell Mater. 2011; 21:15-30.21. McFadden TM et al. Acta Biomater. 2013 Dec; 9(12):9303-16.

22. Keogh MB et al. Cell and Tissue Research. 2010 Apr; 340(1): 169-177.23. Alhag M et al. Oral Maxillofac Surg. 2011 Mar; 15(1):31-9 24. Stack JD et al. J Tissue Eng Regen Med. 2016 doi: 10.1002/term.2173.25. Levingstone TJ et al. Biomaterials 2016: 87: 69-81.26. Levingstone TJ et al. Acta Biomater. 2016 Mar 1;32:149-60.